Biomerica, Inc. (BMRA)
Stock Price Chart
Key Info
| Market Cap | 66.28M |
| Revenue (ttm) | 6.64M |
| Net Income (ttm) | -3.48M |
| Shares Out | 11.75M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 19, 2020 |
| Last Price | $5.64 |
| Previous Close | $5.84 |
| Change ($) | -0.20 |
| Change (%) | -3.42% |
| Day's Open | 5.87 |
| Day's Range | 5.51 - 5.99 |
| Day's Volume | 236,527 |
| 52-Week Range | 2.05 - 23.39 |
More Stats
| Market Cap | 66.28M |
| Enterprise Value | 60.83M |
| Earnings Date (est) | Jan 20, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 11.75M |
| Float | 9.04M |
| EPS (basic) | -0.32 |
| EPS (diluted) | -0.33 |
| FCF / Share | -0.51 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 665,253 |
| Short Ratio | 3.35 |
| Short % of Float | 7.36% |
| Beta | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 9.98 |
| PB Ratio | 4.84 |
| Revenue | 6.64M |
| Operating Income | -3.55M |
| Net Income | -3.48M |
| Free Cash Flow | -5.96M |
| Net Cash | 5.45M |
| Net Cash / Share | 0.46 |
| Gross Margin | 26.83% |
| Operating Margin | -53.43% |
| Profit Margin | -52.40% |
| FCF Margin | -89.69% |
| ROA | -19.62% |
| ROE | -42.98% |
| ROIC | -49.30% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.69 | 5.20 | 5.56 | 5.79 | 5.14 | 4.96 | 5.12 | 6.47 | 6.08 |
| Revenue Growth | 28.69% | -6.53% | -3.93% | 12.68% | 3.58% | -3.09% | -20.89% | 6.44% | - |
| Gross Profit | 1.78 | 1.29 | 1.75 | 2.02 | 1.52 | 1.54 | 1.67 | 2.43 | 2.30 |
| Operating Income | -2.40 | -2.41 | -1.48 | -0.95 | -0.83 | -0.67 | -0.45 | 0.51 | 0.50 |
| Net Income | -2.34 | -2.39 | -1.47 | -0.91 | -1.50 | -0.33 | -0.22 | 0.54 | 0.55 |
| Shares Outstanding | 10.17 | 9.21 | 8.57 | 8.33 | 7.63 | 7.55 | 7.37 | 7.02 | 6.89 |
| Earnings Per Share | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.07 | 0.08 |
| EPS Growth | - | - | - | - | - | - | - | -12.5% | - |
| Operating Cash Flow | -4.30 | -2.24 | -1.17 | -0.72 | -0.21 | -0.41 | -0.86 | 1.39 | 0.15 |
| Capital Expenditures | -0.03 | -0.10 | -0.13 | -0.10 | -0.09 | -0.01 | -0.14 | -0.26 | -0.16 |
| Free Cash Flow | -4.33 | -2.35 | -1.30 | -0.82 | -0.30 | -0.41 | -1.00 | 1.14 | -0.02 |
| Cash & Equivalents | 8.64 | 0.69 | 1.20 | 1.23 | 1.89 | 1.09 | 1.51 | 2.47 | 1.08 |
| Total Debt | 1.57 | - | - | - | - | - | - | - | 0.04 |
| Net Cash / Debt | 7.07 | 0.69 | 1.20 | 1.23 | 1.89 | 1.09 | 1.51 | 2.47 | 1.03 |
| Assets | 17.26 | 5.25 | 5.22 | 5.02 | 5.73 | 6.12 | 6.47 | 6.39 | 5.57 |
| Liabilities | 3.05 | 1.26 | 0.90 | 0.53 | 0.51 | 0.52 | 0.56 | 0.56 | 0.59 |
| Book Value | 14.21 | 3.98 | 4.33 | 4.49 | 5.22 | 5.60 | 5.91 | 5.83 | 4.98 |
Company Profile
Company Details
| Full Name | Biomerica, Inc. |
| Country | United States |
| Employees | 65 |
| CEO | Zackary S. Irani |
Stock Information
| Ticker Symbol | BMRA |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: BMRA |
Description
Biomerica, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.